

Livalo[®] (pitavastatin) – First-time generic

- On November 2, 2023, [Teva launched](#) an AB-rated generic version of Eli Lilly and Kowa Pharmaceuticals' [Livalo \(pitavastatin\)](#) tablets.
 - Other AB-rated approved generics for Livalo include [Aurobindo](#), [Mylan/Viatris](#), [Orient](#), [Sawai](#), and [Zydus](#). Launch is pending for these generics.
- Livalo is approved as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia and adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia.
- Pitavastatin is also available as brand [Zypitamag](#) tablets.
 - Zypitamag is approved as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol, LDL-C, apolipoprotein B, triglycerides, and to increase high-density lipoprotein cholesterol.
 - Zypitamag is not approved for pediatric use because of marketing exclusivity rights.